Crinetics Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Crinetics Pharmaceuticals, Inc. (CRNX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-03
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.75M.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$3.12M, a 400.19% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$329.00K.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $573.00K, a 74.28% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $902.00K.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$14.00K, a 100.29% decline from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $4.91M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.75M 10-Q · filed 2026-08-03 | -$4.87M 10-Q · filed 2026-08-03 | -$5.20M derived: sum of 3 quarters · filed 2026-08-03 | -$4.63M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$3.12M 10-Q · filed 2026-05-07 | -$3.45M derived: sum of 2 quarters · filed 2026-05-07 | -$2.88M derived: sum of 3 quarters · filed 2026-05-07 | -$3.26M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $244.00K derived: sum of 2 quarters · filed 2026-02-26 | -$137.00K derived: sum of 3 quarters · filed 2026-08-03 | $902.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $573.00K 10-Q · filed 2025-11-06 | $192.00K derived: sum of 2 quarters · filed 2026-08-03 | $1.23M 10-Q · filed 2025-11-06 | $156.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$381.00K 10-Q · filed 2026-08-03 | $658.00K 10-Q · filed 2026-08-03 | -$417.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.81M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.04M 10-Q · filed 2026-05-07 | -$36.00K derived: sum of 2 quarters · filed 2026-05-07 | $2.19M derived: sum of 3 quarters · filed 2026-05-07 | $1.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.15M derived: sum of 2 quarters · filed 2026-02-26 | $813.00K derived: sum of 3 quarters · filed 2026-02-26 | -$14.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.23M 10-Q · filed 2025-11-06 | $1.89M derived: sum of 2 quarters · filed 2025-11-06 | $1.06M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$340.00K 10-Q · filed 2025-08-07 | -$1.17M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$827.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.91M 10-K · filed 2026-02-26 |